1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Talon Therapeutics, Inc. – Product Pipeline Review – 2013

Talon Therapeutics, Inc. – Product Pipeline Review – 2013

  • April 2013
  • -
  • Global Markets Direct
  • -
  • 67 pages

Talon Therapeutics, Inc. – Product Pipeline Review – 2013

Summary

Global Market Direct’s pharmaceuticals report, “Talon Therapeutics, Inc. - Product Pipeline Review - 2013” provides data on the Talon Therapeutics, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Talon Therapeutics, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Talon Therapeutics, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Talon Therapeutics, Inc. - Brief Talon Therapeutics, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Talon Therapeutics, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Talon Therapeutics, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Talon Therapeutics, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Talon Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Talon Therapeutics, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Talon Therapeutics, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Talon Therapeutics, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Talon Therapeutics, Inc. and identify potential opportunities in those areas.

Table Of Contents

Talon Therapeutics, Inc. - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Talon Therapeutics, Inc. Snapshot 5
Talon Therapeutics, Inc. Overview 5
Key Information 5
Key Facts 5
Talon Therapeutics, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Talon Therapeutics, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Talon Therapeutics, Inc. - Pipeline Products Glance 10
Talon Therapeutics, Inc. - Late Stage Pipeline 10
Registration Filed Products/Combination Treatment Modalities 10
Phase III Products/Combination Treatment Modalities 11
Talon Therapeutics, Inc. Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
Talon Therapeutics, Inc. - Drug Profiles 14
menadione 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
topotecan hydrochloride 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
vincristine sulfate 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
vinorelbine tartrate 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
Talon Therapeutics, Inc. - Pipeline Products by Route of Administration 23
Talon Therapeutics, Inc. - Pipeline Products By Mechanism of Action 24
Talon Therapeutics, Inc. - Recent Pipeline Updates 25
Talon Therapeutics, Inc. - Dormant Projects 29
Talon Therapeutics, Inc. - Company Statement 30
Talon Therapeutics, Inc. - Locations And Subsidiaries 32
Head Office 32
Talon Therapeutics, Inc., Recent Developments 33
Talon Therapeutics, Inc.- Press Release 33
Nov 29, 2010: Hana Biosciences To Present Data On Marqibo At ASH Annual Meeting 33
Jul 08, 2010: Hana Biosciences Receives US Patent For Menadione For Prevention And Treatment Of EGFR Inhibitor Cancer Therapy-Associated Rash 33
Jun 07, 2010: Hana Biosciences Reports Data From Pivotal Phase II Trial Of Marqibo In Advanced Relapsed/Refractory Adult Ph(-) Acute Lymphoblastic Leukemia 34
Mar 30, 2010: Hana Receives Notice Of Allowance For Menadione Patent For Prevention And Treatment Of EGFR Inhibitor Cancer Therapy-Associated Rash 35
Mar 03, 2010: Hana Biosciences Announces New Positive Interim Efficacy Results In Pivotal rALLy Clinical Trial Of Marqibo In Acute Lymphoblastic Leukemia 36
Financial Deals Landscape 37
Talon Therapeutics, Inc., Deals Summary 37
Talon Therapeutics, Inc., Pharmaceuticals and Healthcare, Deal Details 38
Partnerships 38
Hana Biosciences Enters Into Agreement With Center for Cancer Research 38
Licensing Agreements 40
Tekmira Pharma Amends Licensing Agreement With Hana Biosciences 40
NovaDel Amends Its Licensing Agreement With Hana Biosciences 55
Par Pharma Enters Into Licensing Agreement With Hana Biosciences 56
Equity Offering 58
Talon Therapeutics Completes Private Placement Of Preferred Stock For $11 Million 58
Hana Biosciences Completes First Tranche Of Private Placement For $40 Million 60
Hana Biosciences Completes Private Placement Of $12.4 Million 62
Hana Biosciences Completes Private Placement Of $5 Million 64
Appendix 66
Methodology 66
Coverage 66
Secondary Research 66
Primary Research 66
Expert Panel Validation 66
Contact Us 67
Disclaimer 67



List of Tables

Talon Therapeutics, Inc., Key Information 5
Talon Therapeutics, Inc., Key Facts 5
Talon Therapeutics, Inc. - Pipeline by Indication, 2013 7
Talon Therapeutics, Inc. - Pipeline by Stage of Development, 2013 8
Talon Therapeutics, Inc. - Monotherapy Products in Pipeline, 2013 9
Talon Therapeutics, Inc. - Filed, 2013 10
Talon Therapeutics, Inc. - Phase III, 2013 11
Talon Therapeutics, Inc. - Phase II, 2013 12
Talon Therapeutics, Inc. - Phase I, 2013 13
Talon Therapeutics, Inc. - Pipeline By Route of Administration, 2013 23
Talon Therapeutics, Inc. - Pipeline Products By Mechanism of Action, 2013 24
Talon Therapeutics, Inc. - Recent Pipeline Updates, 2013 25
Talon Therapeutics, Inc. - Dormant Developmental Projects,2013 29
Talon Therapeutics, Inc., Deals Summary 37
Hana Biosciences Enters Into Agreement With Center for Cancer Research 38
Tekmira Pharma Amends Licensing Agreement With Hana Biosciences 40
NovaDel Amends Its Licensing Agreement With Hana Biosciences 55
Par Pharma Enters Into Licensing Agreement With Hana Biosciences 56
Talon Therapeutics Completes Private Placement Of Preferred Stock For $11 Million 58
Hana Biosciences Completes First Tranche Of Private Placement For $40 Million 60
Hana Biosciences Completes Private Placement Of $12.4 Million 62
Hana Biosciences Completes Private Placement Of $5 Million 64



List of Figures

Talon Therapeutics, Inc. - Pipeline by Indication, 2013 7
Talon Therapeutics, Inc. - Pipeline by Stage of Development, 2013 8
Talon Therapeutics, Inc. - Monotherapy Products in Pipeline, 2013 9
Talon Therapeutics, Inc. - Pipeline By Route of Administration, 2013 23
Talon Therapeutics, Inc. - Pipeline Products By Mechanism of Action, 2013 24

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.